Lv11
32 积分 2022-02-28 加入
DEVELOPMENT OF THE PIN-POINTTM PLATFORM: A VERSATILE BASE EDITING TECHNOLOGY WITH BROAD CAS ENZYME AND DEAMINASE COMPATIBILITY FOR CELL AND GENE THERAPY
6小时前
求助中
DEVELOPMENT OF THE PIN-POINTTM PLATFORM: A VERSATILE BASE EDITING TECHNOLOGY WITH BROAD CAS ENZYME AND DEAMINASE COMPATIBILITY FOR CELL AND GENE THERAPY
6小时前
已完结
High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia
3个月前
已完结
High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia
3个月前
已关闭
CAR T cell immunotherapy for human cancer
4个月前
已完结
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
6个月前
已完结
Dual targeting CAR-T cells for B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma
7个月前
已关闭
An expert-driven literature review of “negative” chemicals for developmental neurotoxicity (DNT) in vitro assay evaluation
7个月前
已完结
Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities
8个月前
已完结
Allogeneic double‐negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first‐in‐human phase I study
8个月前
已完结
皖公网安备34019202002308
